Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

Ling Dong, Bin Meng, Xinwei Zhang, Xiuyu Song, Ximei Zhang, Qiongli Zhai, Xia Liu, Yun Hou, Wei Li, Xianhuo Wang, Huaqing Wang, Kai Fu, Huilai Zhang

Research output: Contribution to journalArticle

Abstract

Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalChinese Journal of Clinical Oncology
Volume43
Issue number9
DOIs
StatePublished - Jan 1 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
anaplastic lymphoma kinase
Lymphoma
Phosphotransferases
Transplantation
Recurrence
Therapeutics

Keywords

  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK + DLBCL)
  • Crizotinib
  • Multiple disciplinary team (MDT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical decision on a patient with ALK+ diffuse large B cell lymphoma. / Dong, Ling; Meng, Bin; Zhang, Xinwei; Song, Xiuyu; Zhang, Ximei; Zhai, Qiongli; Liu, Xia; Hou, Yun; Li, Wei; Wang, Xianhuo; Wang, Huaqing; Fu, Kai; Zhang, Huilai.

In: Chinese Journal of Clinical Oncology, Vol. 43, No. 9, 01.01.2016, p. 385-391.

Research output: Contribution to journalArticle

Dong, L, Meng, B, Zhang, X, Song, X, Zhang, X, Zhai, Q, Liu, X, Hou, Y, Li, W, Wang, X, Wang, H, Fu, K & Zhang, H 2016, 'Clinical decision on a patient with ALK+ diffuse large B cell lymphoma', Chinese Journal of Clinical Oncology, vol. 43, no. 9, pp. 385-391. https://doi.org/10.3969/j.issn.1000-8179.2016.09.350
Dong, Ling ; Meng, Bin ; Zhang, Xinwei ; Song, Xiuyu ; Zhang, Ximei ; Zhai, Qiongli ; Liu, Xia ; Hou, Yun ; Li, Wei ; Wang, Xianhuo ; Wang, Huaqing ; Fu, Kai ; Zhang, Huilai. / Clinical decision on a patient with ALK+ diffuse large B cell lymphoma. In: Chinese Journal of Clinical Oncology. 2016 ; Vol. 43, No. 9. pp. 385-391.
@article{f1221f34224a443ca0cc09bfe520ff84,
title = "Clinical decision on a patient with ALK+ diffuse large B cell lymphoma",
abstract = "Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.",
keywords = "Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK + DLBCL), Crizotinib, Multiple disciplinary team (MDT)",
author = "Ling Dong and Bin Meng and Xinwei Zhang and Xiuyu Song and Ximei Zhang and Qiongli Zhai and Xia Liu and Yun Hou and Wei Li and Xianhuo Wang and Huaqing Wang and Kai Fu and Huilai Zhang",
year = "2016",
month = "1",
day = "1",
doi = "10.3969/j.issn.1000-8179.2016.09.350",
language = "English (US)",
volume = "43",
pages = "385--391",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "9",

}

TY - JOUR

T1 - Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

AU - Dong, Ling

AU - Meng, Bin

AU - Zhang, Xinwei

AU - Song, Xiuyu

AU - Zhang, Ximei

AU - Zhai, Qiongli

AU - Liu, Xia

AU - Hou, Yun

AU - Li, Wei

AU - Wang, Xianhuo

AU - Wang, Huaqing

AU - Fu, Kai

AU - Zhang, Huilai

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.

AB - Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regimen is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This article presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibitor Crizotinib.

KW - Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK + DLBCL)

KW - Crizotinib

KW - Multiple disciplinary team (MDT)

UR - http://www.scopus.com/inward/record.url?scp=85019058504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019058504&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2016.09.350

DO - 10.3969/j.issn.1000-8179.2016.09.350

M3 - Article

VL - 43

SP - 385

EP - 391

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 9

ER -